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SUMMARY.Background: Several studies have reported that neutrophil–lymphocyte ratio (NLR) can predict
survival in esophageal and gastroesophageal junction adenocarcinoma, as it reflects systemic inflammation. Hence,
we aimed to determine whether baseline NLR holds prognostic value for esophageal adenocarcinoma patients
treated with neoadjuvant chemotherapy (nCT) followed by surgery.Methods:We studied the data of 139 patients
that received nCT before undergoing esophagectomy with curative intent, all identified from a prospectively
maintained database (1998–2016). Pretreatment hematology reports were used to calculate the baseline NLR. A
receiver operating characteristic curve (ROC-curve) was plotted to determine an optimal cutoff value.NLRquartiles
were used to display possible differences between groups in relation to overall survival (OS) and disease-free survival
(DFS) using the method of Kaplan–Meier. Cox regression analysis was performed to assess the prognostic value of
NLR. Results: The median OS and DFS times were 46 months (interquartile range [IQR]: 19–166) and 30 months
(IQR: 13–166], respectively, for the entire cohort. The ROC-curve showed that NLR has no discriminating power
for survival status (area under the curve= 0.462) and therefore no optimal cutoff value could be determined. There
were no statistically significant differences in median OS times for NLR quartiles: 65 (Q1), 32 (Q2), 45 (Q3), and
46 months (Q4) (P = 0.926). Similarly, DFS showed no difference between quartile groups, with median survival
times of 27 (Q1), 19 (Q2), 36 (Q3), and 20 months (Q4) (P = 0.973). Age, pN, pM, and resection margin were
independent prognostic factors for both OS and DFS. On the contrary, NLR was not associated with OS or DFS
in univariable and multivariable analyses. Conclusion: Baseline NLR holds no prognostic value for esophageal and
gastroesophageal junction adenocarcinoma patients treated with nCT in this study, in contrast to other recently
published papers. This result questions the validity of NLR as a reliable prognostic indicator and its clinical
usefulness in these patients.
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INTRODUCTION
Esophageal adenocarcinoma (EAC) is an aggressive
solid tumor and the rising incidence over the last
three decades inWestern industrialized countries is of
concern, given the poor prognosis.1, 2 Currently used
multimodality approaches do not benefit all patients
and are associated with a considerable rate of adverse
events, creating a need to better identify and differ-
entiate patients that have a poor response to (neoad-
juvant) treatment or risk of life-threatening toxicity
and may be considered for alternative treatments.3–6
Complete or major pathologic response as deter-
mined in the resection specimen is applied as a
prognostic indicator of overall survival (OS) after
neoadjuvant therapy.7 Recent research, however,
questions its validity as a surrogate endpoint for OS.8
Ideally, pretreatment biomarkers could serve as
novel predictors of survival after preoperative therapy
plus surgery. As there has been little progress in terms
of clinically applicable molecular predictors for EAC,
alternative biomarkers are under active investigation.
Although the behavior and development of cancer are
influenced and determined by numerous molecular
1
D
ow
nloaded from
 https://academ
ic.oup.com
/dote/article-abstract/33/6/doz082/5610875 by Erasm
us U
niversiteit R
otterdam
 user on 24 June 2020
2 Diseases of the Esophagus
processes and patient-related factors, there is evidence
that both tumor-related inflammation and systemic
inflammation play a significant role in the tumorige-
nesis as it predisposes the microenvironment to tumor
development.9, 10 This has led to an increasing interest
in various inflammation-based markers and scores
and several of these have been reported to feature
prognostic value in solid tumors, as they reflect the
extent of antitumor response or systemic inflamma-
tion.11–13
A marker of systemic inflammation, the neu-
trophil–lymphocyte ratio (NLR), has also been
associated with prognosis in a variety of tumors,
including esophageal and gastric carcinomas.14–16
As the NLR can be calculated from routine blood
tests, it is potentially an economical and clinically
applicable prognostic biomarker. A handful of studies
have reported that NLR determined before therapy is
associated with survival in EAC patients after various
treatment approaches, but a standardized cutoff value
to stratify patients remains undetermined.17 There-
fore, we set out to determine the prognostic value
and an optimal cutoff value of pretreatment NLR
in patients with esophageal and gastroesophageal
junction adenocarcinomas treated with neoadjuvant
chemotherapy (nCT).
METHODS
Patients
The prospectively maintained Upper-GI database
from the Department of Surgery, Princess Alexandra
Hospital (Brisbane, Australia) was searched for
patients who underwent curative esophagectomy
after nCT for esophageal and gastroesophageal
junction adenocarcinomas between February 1998
and August 2016. Approval was granted by the
Human Research Ethics Committee to maintain
the database (HREC/16/QPAH/614). Patients were
considered for neoadjuvant therapy if clinically staged
cT1N+ or >cT2N0 and fit for esophagectomy.
Hematology reports from routine blood tests were
used to calculate the baseline NLR, dividing absolute
neutrophil count by absolute lymphocyte count. All
blood tests used to calculate NLR were taken prior
to chemotherapy treatment, within 1 week of the
first consultation. For inclusion, patients needed to
have been administered a minimum of two cycles
of platinum-based chemotherapy. Exclusion criteria
were the absence of pretreatment hematology reports
as well as other synchronously active malignancies.
Data were collected from eligible patients comprising
patient characteristics, clinical staging (7th edition of
the American Joint Committee on Cancer-manual18),
operative details, chemotherapy details, pathological
staging and recurrence, and survival status. In case
of multiple available reports, the one closest to
commencement of chemotherapy was used.
Staging, treatment, and follow-up
Clinical staging included endoscopy and computed
tomography (CT) of the chest and abdomen in
all patients. Endoscopic ultrasonography was used
to clarify tumor and nodal staging when neces-
sary. In 2008 fluoro-deoxyglucose-positron emission
tomography scanning was introduced and has been
performed as a routine staging procedure since.
The majority of patients received a chemothera-
peutic regimen based on either a combination of
5-fluoruracil (5-FU) and cisplatin as per OEO2-
trial19 or as per MAGIC-trial20, administering three
cycles preoperative and three cycles postoperative
with a combination of 5-FU, cisplatin, and epirubicin
(ECF). A small number of patients received two
cycles of triplet chemotherapy consisting of docetaxel,
cisplatin, and 5-FU (DCF) before surgery, as per
a trial regimen. One patient received epirubicin,
oxaliplatin, and 5-FU (EOF). Within 3-6 weeks
after completing chemotherapy patients underwent
curative esophagectomy. The surgical techniques used
have been previously described.21 Follow-up consisted
of clinical assessment, including physical and history
examination, at three-month intervals after surgery
for the first 2 years, 6-month intervals up to five years,
where after annually up to ten years. In follow up
imaging (typically a CT scan of the chest abdomen
and pelvis) and endoscopy were performed when
clinically indicated. Additional investigations were
carried out on individual basis. Specimens with tumor
cells present within 1mm of the resectionmargin were
considered to be an R1 resection.
Statistical analysis
A receiver operating characteristic curve (ROC-curve)
was plotted to determine an optimal cutoff value.
NLR quartiles are used to display possible differences
between groups in relation to OS and disease-free
survival (DFS). Categorical variables are presented as
frequencies with percentage and in case of continuous
variables as medians with interquartile range (IQR).
Pearson’s χ2 test and Fisher–Freeman–Halton exact
test were used to compare categorical data, as appro-
priate, and the Kruskal–Wallis test was used to com-
pare nonparametric continuous data. OS was defined
as the time between the date of first consultation and
death by any cause or last follow-up. DFSwas defined
as the time between surgery and histologically proven
or radiologically evident recurrence, last follow-up or
date of death. OS and DFS curves were estimated by
the method of Kaplan–Meier and differences tested
with the log-rank test. Cox regression analysis was
performed to assess the prognostic significance of
NLR and other clinical and pathological variables.
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Table 1 Patient characteristics
Variables n
Age, median (IQR, year) 62 (55–67)
Gender (male/female) 123/16
ASA score (1/2/3) 11/93/35
Tumor location (mid/low/GE junction) 30/105/4
cT (T1/T2/T3) 3/58/78
cN (N0/N1/N2) 87/49/3
cM (M0/M1) 139/0
Tumor differentiation (poor/moderate/well) 100/36/3
ypT (T1/T2/T3/T4) 24/21/81/13
ypN (N0/N1/N2/N3) 48/33/36/22
ypM (M0/M1) 136/3
Tumor size, median (IQR, cm) 3 (2–4)
Resection margin (R0/R1/R2) 116/22/1
Mandard score (I/II/III/IV/V/missing) 0/12/25/61/36/5
NLR, median (IQR) 2.46 (1.72–3.23)
IQR, interquartile range; ASA, American Society of Anesthesiolo-
gists; GO, gastroesophageal; NLR neutrophil–lymphocyte ratio.
Variables with a P-value< 0.1 in univariable analyses
were included in the multivariable model. All tests
were two-sided and the threshold for significance was
set at P < 0.05 (two-sided). Statistical analysis was
performed using SPSS v25.0 (IBM Corp, Armonk,
NY, USA).
RESULTS
Patients and cutoff value
A total of 144 patients were identified who matched
the inclusion criteria and had hematology reports
available from blood tests prior to treatment. Five
patients did not have sufficient survival data and
were excluded from analysis, resulting in 139 eligible
patients. Table 1 shows baseline patient characteris-
tics. Median NLR was 2.46 (IQR; 1.72– 3.23) across
all patients. The ROC-curve showed that NLR has no
discriminating power for survival status (area under
the curve= 0.462, Fig. 1) and therefore no optimal
cutoff value could be determined. NLR quartiles
used to assess the prognostic value of NLR were
as follows: ≤1.718 (Q1); 1.72–2.47 (Q2); 2.48–3.15
(Q3); ≥3.16 (Q4). Table 2 displays the distribution
of patient and tumor characteristics between the
NLR quartiles. None of the assessed variables showed
statistically significant differences between NLR
quartiles. Also, no trend or statistically significant
differences were found regarding grade 3/4 adverse
events during chemotherapy among NLR quartiles
(P-value= 0.967; data not shown).
OS and DFS
The median OS was 46 months [IQR: 19–166] for the
entire cohort. Both uni- andmultivariable analyses for
OS are shown in Table 3. In univariable analyses, age,
resection margin, pathological T-, N-, and M stages
were associatedwithOS (P< 0.2) and therefore added
to the multivariable model. NLR, assessed as a con-
tinuous variable, was not associated with OS in uni-
variable analysis. Multivariable analysis showed that
the adjusted hazard ratio (HR) was not predictive for
OS (HR 0.922; CI 95% 0.771–1.103;P-value= 0.375).
The median (IQR) OS times for NLR quartiles were
65 (20–166) (Q1), 32 (17-not reached) (Q2), 45 (19–
95) (Q3) and 46 (19-not reached) months (Q4), with
no significant difference (P = 0.926). Figure 2A dis-
plays the Kaplan–Meier curves for OS for the NLR
quartiles.
The medianDFS was 27 months [IQR: 10–164] for
the entire cohort. Table 4 shows uni- and multivari-
able analyses for DFS. Age, resection margin, and
pathological T-, N-, and M stages were associated
with DFS in univariable analyses, whereas NLR was
not. In multivariable analysis, the adjusted HR for
NLR was 0.951 (CI 95% 0.818–1.107; P-value 0.517)
and therefore was not an independent predictor for
DFS. The median DFS times showed no difference
between NLR quartile groups either, with median
DFS times of 27 (13–164) (Q1), 19 (10-not reached)
(Q2), 36 (9–93) (Q3) and 20 (9-not reached) months
(Q4, P = 0.973). Figure 2B displays the Kaplan–
Meier curves for DFS for the NLR quartiles.
DISCUSSION
An underlying mechanism that could possibly explain
an association between elevated NLR and poor sur-
vival has not been clearly established yet. It is evident
that both neutrophils and lymphocytes play a fun-
damental role in the inflammatory response. There
is data that suggest that tumors with a significant
rate of infiltrating lymphocytes are associated with a
better cytotoxic response.22, 23 Neutrophilia inhibits
the antitumor activity of lymphocytes diminishing
the beneficial effect of infiltrating lymphocytes on
response to therapy and suppresses the cytolytic abil-
ity of natural killer cells and activated T cells.24–26
Moreover, neutrophils are known to release several
growth factors, including vascular endothelial growth
factor, promoting angiogenesis and can thus stimu-
late the microenvironment of a tumor.27 Circulating
neutrophil and lymphocyte counts may reflect these
tumor-level effects. In this study, however, baseline
NLR was not associated with OS or DFS. NLR had
no discriminatory power for each quartile and no
optimal cutoff point could be determined based on
the ROC-curve. Regarding the latter, the area under
the curve value (AUC= 0.462) found in the ROC-
curve points out that NLR is not a valid marker
for predicting survival status. The (adjusted) hazard
ratios showed that NLR is not an independent prog-
nostic factor for OS or DFS. Moreover, the NLR was
not predictive for pathological response according to
Mandard score.
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Fig. 1 ROC-curve for survival status; area under the curve= 0.462.
Overall, these findings do not concur with most
of the published literature.14 A meta-analysis of
seven studies found NLR to be prognostic for
OS in esophageal cancer, but not for DFS (76%
squamous cell carcinoma; 20% adenocarcinoma;
4% other).15 Of note was the significant between-
study heterogeneity, partly explained by the variety
of treatment approaches. An additional subgroup
analysis showed that NLR was not prognostic in
patients who underwent surgical resection alone. This
corresponds with a recent study including over 1300
patients with gastroesophageal and gastric adeno-
carcinomas without receiving nCT.28 In contrast, a
study subsequent to the REAL-2 trial, which included
908 patients with both gastric and esophageal
carcinoma (88% adenocarcinoma; 10% squamous
cell carcinoma; 2% other), all treated with a triplet
chemotherapy regimen (ECF/epirubicin, cisplatin,
and capecitabine (ECX)/EOF/epirubicin, oxaliplatin,
and capecitabine (EOX),29 reported a predetermined
high NLR (>3) was significantly associated with
poor survival in a relatively homogeneous group
of patients. An important difference to our study,
however, is that the majority of the included patients
had metastatic disease, reflected by their reported
median OS times of 9.1 and 12.7 months for high and
low NLR, respectively, compared to our median OS
of 46 months for the entire cohort. Interestingly, their
median baseline NLR of 3.7 was considerably higher
than found in the present study and other comparable
literature which did not include metastasized tumors,
indirectly suggesting that NLR may reflect the extent
of dissemination.30, 31 A retrospective analysis of 117
patients with adenocarcinoma supports this theory
by confirming that the NLR was an independent pre-
dictor of the discovery of peritoneal and/or metastatic
disease.32 Moreover, Conway et al. recently reported
an NLR≥3 to be independently associated with early
disease progression resulting in unresectable disease in
patients receiving nCT for gastroesophageal junction
adenocarcinoma.30 The abovementioned findings, in
addition to adequate staging and patient selection,
might have played a role in our negative results as no
patients with stage IV disease were included.
Despite the wide array of literature reporting NLR
to be of prognostic value in various types of solid
tumors, there is a lack of consensus regarding the opti-
mal cutoff value to stratify patients.17 To be of signifi-
cance as a prognostic tool in the decision-making pro-
cess, a standardized cutoff value is needed to divide
patients into risk groups based on NLR. At this time,
this has not been the case and thus the use of NLR
has not been implemented in the clinic. Irrespective of
our results, the diversity of NLR cutoff values, rang-
ing from 2 to 5, used by previous studies, reporting
significant differences in survival times, questions the
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Table 2 Distribution of patient and tumor characteristics according to NLR quartiles
Q1 Q2 Q3 Q4
Variables n (%) n (%) n (%) n (%) P-value
Age, median (IQR, year) 63 (55–67) 61 (55–67) 63 (51–68) 61 (56–67) 0.956
Gender 0.487
Female 6 (17.1) 5 (14.3) 2 (5.9) 3 (8.6)
Male 29 (82.9) 30 (85.7) 32 (94.1) 32 (91.4)
ASA score 0.509
1 2 (5.7) 2 (5.7) 4 (11.8) 3 (8.6)
2 24 (68.6) 20 (57.1) 25 (73.5) 24 (68.6)
3 9 (25.7) 13 (37.1) 5 (14.7) 8 (22.9)
Tumor differentiation 0.678
Poor 26 (74.3) 26 (74.3) 24 (70.7) 24 (68.6)
Moderate 7 (20) 9 (25.7) 10 (29.4) 10 (28.6)
Well 2 (5.7) - - 1 (2.9)
ypT stage 0.748
T1-2 9 (25.7) 11 (31.4) 12 (35.3) 13 (37.1)
T3-4 26 (74.3) 24 (68.6) 22 (64.7) 22 (62.9)
ypN stage 0.696
N0 15 (42.9) 11 (31.4) 11 (32.4) 11 (31.4)
N1-3 20 (57.1) 24 (68.6) 23 (67.6) 24 (68.6)
ypM stage 0.902
M0 34 (97.1) 35 (100) 33 (97.1) 34 (97.1)
M1 1 (2.9) - 1 (2.9) 1 (2.9)
Tumor size (cm) 0.087
Median (IQR) 3 (1.5–4) 2.5 (2–3.5) 2.8 (2–3.6) 3.5 (2.3–4.5)
Resection margin 0.186
R0 26 (74.3) 32 (91.4) 27 (79.4) 31 (88.6)
R1/R2 9 (25.7) 3 (8.6) 7 (20.6) 4 (11.4)
Mandard score 0.920
TRG I - - - -
TRG II 4 (11.8) 3 (9.1) 1 (3) 4 (11.8)
TRG III 6 (17.6) 5 (15.2) 6 (18.2) 8 (23.5)
TRG IV 14 (41.2) 15 (45.5) 18 (54.5) 14 (41.2)
TRG V 10 (29.4) 10 (30.3) 8 (24.2) 8 (23.5)
Lymph node yield 0.992
Median (IQR) 1 (0–5) 2 (0–6) 1.5 (0–5.25) 2 (0–5)
Positive lymph node yield 0.843
Median (IQR) 27 (20–34) 26 (19–34) 27.5 (18.75–33.25) 25 (21–33)
IQR, interquartile range; ASA, American Society of Anesthesiologists; TRG, tumor regression grade; Q1 ≤ 1.718; Q2: 1.72–2.47; Q3:
2.48–3.15; Q4≥ 3.16.
reliability of the NLR as prognostic biomarker.16, 17
Adding the evidence that the NLR is also influenced
by ethnical and behavioral characteristics, it explains
why measuring the NLR is not being utilized by clin-
icians.33
Despite all the blood tests being taken prior to
commencing treatment, a limitation of our study was
the considerable variety in point of time the blood
tests were taken. Because of this, we cannot rule out
that other inflammatory conditionsmay have affected
some NLR values in this data set. However, it is
not likely considering the fact that active infection
contraindicates systemic therapy. Other limitations
are the retrospective nature of this analysis and the
relatively small number of patients. However, multi-
ple smaller studies did find an association between
pretreatment NLR and survival in esophageal and
gastric cancer.34–36 Moreover, our results do not trend
toward being significant suggesting that a lack of
statistical power is not likely to be a major factor
in our negative findings. To maximize the power of
the data, we chose to use the NLR as a continuous
variable in the regression analysis.37 As we could not
determine an optimal cutoff value for the NLR in this
cohort, we opted to use NLR quartiles as they could
virtually display an incremental effect of increasing
NLR in a survival curve.
Our primary aim was to assess if the NLR could
be used as a stratification tool for risk groups and
possibly to predict therapy response. Determining the
NLR after chemotherapy would be less useful for
that purpose as patients already had therapy, but a
change in NLR during chemotherapy might be an
area for future research. Currently, there are no stud-
ies evaluating a possible association of an increase or
decrease of the NLR during chemotherapy and sur-
vival outcomes. Note that the NLR can be impacted
by the chemotherapy itself, as the chemotherapy reg-
imens used can cause neutropenia. Mayers et al.38
reported that a higher incidence of myelosuppression,
possibly correlated with a greater dose of chemother-
apy, was associated with better survival in patients
with early-stage breast carcinoma treated with adju-
vant chemotherapy. Hence, it is possible preoperative
NLR, after receiving nCT, might be a better prognos-
ticator.
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Table 3 Cox regression analysis for OS
Univariable analysis Multivariable analysis
Variables n HR CI (95%) P-value HR CI (95%) P-value
Age (year) 139 0.977 0.953–1.001 0.065 0.961 0.935–0.988 0.004
Gender
Male 123 Ref. –
Female 16 0.605 0.263–1.394 0.238
Tumor differentiation
Poor 100 Ref. –
Moderate 36 0.872 0.523–1.455 0.601
Well 3 0.326 0.043–2.494 0.281
Tumor length (centimeter) 139 1.053 0.939–1.181 0.379
Year of surgery
1998-2007 61 Ref. –
2008-2016 78 0.814 0.515–1.286 0.378
Resection margin
R0 116 Ref. – Ref. –
R1/R2 23 3.801 2.225–6.492 <0.001 2.555 1.4–4.662 0.002
ypT stage
T1-2 45 Ref. – Ref. –
T3-4 94 2.416 1.391–4.196 0.002 1.101 0.599–2.026 0.756
ypN stage
N0 48 Ref. – Ref. –
N1-3 91 5.273 2.829–9.826 <0.001 5.301 2.701–10.404 <0.001
ypM stage
M0 136 Ref. – Ref. –
M1 3 16.302 4.662–57.500 <0.001 4.619 1.22–17.482 0.024
NLR 139 0.944 0.803–1.110 0.486 0.922 0.771–1.103 0.375
HR, hazard ratio; CI, confidence interval; NLR, neutrophil–lymphocyte ratio. For all continuous variables: HR reflects the risk per one
absolute unit increase. Bold values are statistically significant (P < 0.05).
Table 4 Cox regression analysis for DFS
Univariable analysis Multivariable analysis
Variables n HR CI (95%) P-value HR CI (95%) P-value
Age (year) 139 0.979 0.956–1.003 0.084 0.967 0.942–0.992 0.011
Gender
Male 123 Ref. –
Female 16 0.629 0.290-1.367 0.242
Tumor differentiation
Poor 100 Ref. –
Moderate 36 0.811 0.493–1.334 0.410
Well 3 0.340 0.044–2.608 0.299
Tumor length (cm) 139 1.041 0.954–1.137 0.365
Year of surgery
1998-2007 61 Ref. –
2008-2016 78 0.952 0.611–1.484 0.829
Resection margin
R0 116 Ref. – Ref. –
R1/R2 23 3.202 1.915–5.354 <0.001 2.171 1.220–3.865 0.008
ypT stage
T1-2 45 Ref. – Ref. –
T3-4 94 2.205 1.318–3.688 0.003 1.015 0.570–1.808 0.959
ypN stage
N0 48 Ref. - Ref. –
N1-3 91 4.630 2.589–8.280 <0.001 4.549 2.400–8.620 <0.001
ypM stage
M0 136 Ref. – Ref. –
M1 3 39.359 10.127–152.205 <0.001 14.236 3.453–58.781 <0.001
NLR 139 0.974 0.846–1.121 0.709 0.951 0.818–1.107 0.517
HR, hazard ratio; CI, confidence interval; NLR, neutrophil–lymphocyte ratio. For all continuous variables: HR reflects the risk per one
absolute unit increase. Bold values are statistically significant (P < 0.05).
To conclude, our study showed that, in contrast
to some literature, baseline NLR holds no prognostic
value for EAC patients treated with nCT plus surgery.
In addition to the lack of consensus on a standardized
cutoff value, these results question the validity of
NLR as a reliable prognostic indicator and thus its
role as a clinical tool to stratify EAC patients treated
with nCT.
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Fig. 2 A-B OS (A) and DFS (B) according to NLR quartiles.
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